Navigation Links
Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
Date:10/25/2007

ng pain as measured using the Visual Analogue Scale.

Recent studies in post-operative inflammation have used "clinical cure" at Day 15 as the primary endpoint. In these studies, clinical cure was defined as having 5 anterior chamber cells or less and a flare score of zero. Applying these criteria to our data, at Day 15, 73% of subjects on the difluprednate BID regimen reached clinical cure versus 27% of subjects in the placebo group, for a treatment effect of 46% (p<0.0001). In the difluprednate QID group, 71% of subjects reached clinical cure at Day 15.

Difluprednate was well tolerated with few treatment related adverse events. Of particular note, mean intraocular pressure (IOP) for all study groups remained within the normal range throughout the trial. Three subjects (3%) in the BID group, three subjects (3%) in the QID group, and two subjects (1%) in the placebo group met the criterion for a clinically significant rise in IOP, defined as an increase of greater than 10 mmHg from baseline combined with a peak pressure of more than 21 mmHg at any time point during the study period.

The analysis demonstrated comparable clinical efficacy and acceptable safety profiles for both BID and QID dosing of difluprednate.

"These are extremely robust data," said Dr. Michael Korenfeld, an ophthalmologist with Comprehensive Eye Care in Washington, Missouri who was an investigator in the trial. "Being able to treat ocular inflammatory disease with a more convenient dosing regimen and having the potential to offer rapid resolution of inflammation after ocular surgery would represent a meaningful advance for patients."

"Sirion is very excited about these results. When we started this program, we felt that difluprednate had the potential to be a major step forward in the control of ocular inflammation. These results met our highest expectations" said Barry Butler, President and CEO of Sirion. "We look forward to bringing this important new treatment opti
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Sirion Therapeutics Announces Clinical Data to be Presented at the 2007 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... ALEXANDRIA, Va. and WASHINGTON ... of Specialty Pharmacy (NASP) and SmartBrief recently partnered to ... with a snapshot of the top news in the ... specialty pharmacies, pharmaceutical and biotechnology manufacturers, GPOs, distributors and ... free resource will launch on April 27, 2015. ...
(Date:4/27/2015)... -- The North America ... $4,211.2 million by 2019, at a CAGR of 5.0% from ... the North America ophthalmology surgery device ... It also provides a glimpse of the segmentation of this ... tables and figures. http://www.micromarketmonitor.com/market/north-america-ophthalmology-surgery-devices-9102894245.html ...
(Date:4/27/2015)... The North America ... and geography and includes analysis and forecast of revenue. This ... expected to reach $829.9 million by 2019, at a CAGR ... the TOC of the North America Optical microscopy market report, ... also provides a glimpse of the segmentation in this market, ...
Breaking Medicine Technology:NASP and SmartBrief Partner on Specialty Pharmacy SmartBrief 2North America Ophthalmology Surgery Device Market is Expected to Reach $4,211.2 Million by 2019, at a CAGR of 5.0% From 2014 to 2019 2North America Ophthalmology Surgery Device Market is Expected to Reach $4,211.2 Million by 2019, at a CAGR of 5.0% From 2014 to 2019 3North America Optical Microscopy Market is Expected to Reach $829.9 Million by 2019, at a CAGR of 3.0% From 2014 to 2019 2North America Optical Microscopy Market is Expected to Reach $829.9 Million by 2019, at a CAGR of 3.0% From 2014 to 2019 3
... Necessary For Diabetic Patients, BOSTON, Sept. 13 ... the United States alone. Coronary artery,disease (CAD) is a ... ischemia is common, and cardiac death or myocardial,infarction may ... the Detection of Ischemia in Asymptomatic Diabetics (DIAD),Study, presented ...
... Australia, Sept. 12 Sunshine Heart (ASX: SHC),a ... assist,technologies, today announced that it has received conditional ... U.S. Food and Drug,Administration (FDA) to begin its ... in patients with moderate heart failure. C-Pulse is,an ...
Cached Medicine Technology:Screening for Ischemia in Asymptomatic Patients With Type 2 Diabetes: Five- Year Outcomes in the DIAD Study 2Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial 2Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial 3
(Date:4/28/2015)... Colorado spine surgeon Donald Corenman, MD, ... popular spine education website NECKANDBACK.COM and his ... Media. This website has been redesigned to help patients ... spine, causes of neck and back pain, and conditions ... and personally answers questions in the neck and back ...
(Date:4/28/2015)... The buyer power score for ... indicating a medium level of buyer power in the ... equal power during negotiations. One factor helping buyer power ... health insurance policy from an insurance carrier (such as ... choose to self-fund their own policy or forgo insurance ...
(Date:4/28/2015)... It’s not all about the law at the Law ... litigation and plaintiff’s personal injury lawyer that has also served ... also about giving back to the community. This is ... Research Center Innovator’s Network. , “I believe there is a ... can and do good community-focused work in their communities,” said ...
(Date:4/28/2015)... SeniorCare.com has published the Misconception ... problem Americans have regarding aging and long-term care needs. ... services as they age, 63% of Americans do NOT ... the report, Carol Marak of SeniorCare.com interviewed 44 senior ... Care Association and The Scan Foundation. The experts discuss ...
(Date:4/28/2015)... Dead or damaged trees can quickly turn into ... cases, tree removal by a skilled team is recommended as ... , In their latest article , Precision Tree ... property owners today. Each method requires skill and expertise that ... , The article states that, “Tree removal is not “one ...
Breaking Medicine News(10 mins):Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 2Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 2Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 3Health News:New Data for Group Health Insurance Procurement Category Market Research Report from IBISWorld 4Health News:Seattle Attorney Paul Schneiderman Helping to Combat Cancer 2Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2Health News:Tree Removal Methods and Services Discussed in Recent Article by Precision Tree Services 2
... Jan. 28 Prime Companies, Inc. (Pink Sheets: PCIR) ... that will allow it to spin off its wholly ... 2007, to a San Diego firm which, once it ... 15 percent of the new company.The agreement with TransPacific ...
... Essential Hospital Guide to Get Your Loved One Out Alive," by ... Health Book of the Year by Allbooks Review Editor,s Choice Awards ... ... 2009 -- "Critical Conditions: The Essential Hospital Guide to Get Your ...
... of Health Strategies & Solutions, Inc the largest healthcare consultant in ... her expertise in management, governance, finance, operations and medical staff. ... ... The nation,s leading healthcare consulting firm, Health Strategies & ...
... A University of Rochester Medical Center study challenges common assumptions ... some people, surprisingly high levels remain in the body even ... suggests that BPA exposure may come from non-food sources, or ... journal Environmental Health Perspectives published the research online ...
... Jan. 27 Minnesotans with chronic,conditions and disabilities ... under the proposed budget of Gov. Tim Pawlenty, ... Center. , "As a ... thousands of Minnesotans following an illness, surgery or ...
... officials say company distributed ,adulterated, peanut butter products in ... -- The Georgia facility that produced the peanut butter ... in the past distributed questionable peanut butter product, U.S. ... 2008, Peanut Corporation of America, which owns the now-closed ...
Cached Medicine News:Health News:Prime Companies Reaches Agreement to Spin Off Subsidiary; Shareholders Gain 15 Percent Stake in New Telecommunications Company 2Health News:"Critical Conditions" Wins Best Health Book of the Year Awards 2Health News:New Employee of the Nations Largest Healthcare Consulting Firm 2Health News:Rochester study raises new questions about controversial plastics chemical 2Health News:Rochester study raises new questions about controversial plastics chemical 3Health News:Courage Center Experts Disagree With Gov. Pawlenty's Proposed Budget Cuts 2Health News:Courage Center Experts Disagree With Gov. Pawlenty's Proposed Budget Cuts 3Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 2Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 3
Assay for Determination of Initial Thrombin Formation...
Pefakit PiCT UFH Controls...
Pefakit PiCT LMWH Controls...
Pefakit PiCT LMWH Calibrators...
Medicine Products: